These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 27323294)

  • 21. High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1.
    Bu HZ; Magis L; Knuth K; Teitelbaum P
    Rapid Commun Mass Spectrom; 2001; 15(10):741-8. PubMed ID: 11344532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential enantioselectivity and product-dependent activation and inhibition in metabolism of verapamil by human CYP3As.
    Shen L; Fitzloff JF; Cook CS
    Drug Metab Dispos; 2004 Feb; 32(2):186-96. PubMed ID: 14744940
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physiologically based pharmacokinetic modeling to predict complex drug-drug interactions: a case study of AZD2327 and its metabolite, competitive and time-dependent CYP3A inhibitors.
    Guo J; Zhou D; Li Y; Khanh BH
    Biopharm Drug Dispos; 2015 Nov; 36(8):507-19. PubMed ID: 26081137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Marmoset Cytochrome P450 3A4 Ortholog Expressed in Liver and Small-Intestine Tissues Efficiently Metabolizes Midazolam, Alprazolam, Nifedipine, and Testosterone.
    Uehara S; Uno Y; Nakanishi K; Ishii S; Inoue T; Sasaki E; Yamazaki H
    Drug Metab Dispos; 2017 May; 45(5):457-467. PubMed ID: 28196829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing and minimizing time-dependent inhibition of cytochrome P450 3A in drug discovery: a case study with melanocortin-4 receptor agonists.
    Tang W; Stearns RA; Wang RW; Miller RR; Chen Q; Ngui J; Bakshi RK; Nargund RP; Dean DC; Baillie TA
    Xenobiotica; 2008 Nov; 38(11):1437-51. PubMed ID: 18841517
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam.
    van Waterschoot RA; Rooswinkel RW; Sparidans RW; van Herwaarden AE; Beijnen JH; Schinkel AH
    Drug Metab Dispos; 2009 Dec; 37(12):2305-13. PubMed ID: 19752211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib.
    Dong PP; Fang ZZ; Zhang YY; Ge GB; Mao YX; Zhu LL; Qu YQ; Li W; Wang LM; Liu CX; Yang L
    Acta Pharmacol Sin; 2011 Mar; 32(3):399-407. PubMed ID: 21372830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inactivation kinetics and residual activity of CYP3A4 after treatment with erythromycin.
    Ishikawa Y; Akiyoshi T; Imaoka A; Ohtani H
    Biopharm Drug Dispos; 2017 Oct; 38(7):420-425. PubMed ID: 28425104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug-drug interactions and metabolism in cytochrome P450 2C knockout mice: application to troleandomycin and midazolam.
    Grimsley A; Gallagher R; Hutchison M; Pickup K; Wilson ID; Samuelsson K
    Biochem Pharmacol; 2013 Aug; 86(4):529-38. PubMed ID: 23732297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Species differences and substrate specificity of CYP3A heteroactivation by efavirenz.
    Kosugi Y; Takahashi J
    Xenobiotica; 2015 Apr; 45(4):345-52. PubMed ID: 25387130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of CYP3A-mediated testosterone 6β-hydroxylation by tanshinone IIA and midazolam 1-hydroxylation by cryptotanshinone in human liver microsomes.
    Qiu F; Zhang R; Wang G; Gao C; Sun J; Jiang J; Ma Y
    Xenobiotica; 2010 Dec; 40(12):800-6. PubMed ID: 20964620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proluciferin acetals as bioluminogenic substrates for cytochrome P450 activity and probes for CYP3A inhibition.
    Meisenheimer PL; Uyeda HT; Ma D; Sobol M; McDougall MG; Corona C; Simpson D; Klaubert DH; Cali JJ
    Drug Metab Dispos; 2011 Dec; 39(12):2403-10. PubMed ID: 21890735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and validation of a LC-MS/MS method for the in vitro analysis of 1-hydroxymidazolam in human liver microsomes: application for determining CYP3A4 inhibition in complex matrix mixtures.
    Mooiman KD; Maas-Bakker RF; Rosing H; Beijnen JH; Schellens JH; Meijerman I
    Biomed Chromatogr; 2013 Sep; 27(9):1107-16. PubMed ID: 23674377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates.
    Stresser DM; Blanchard AP; Turner SD; Erve JC; Dandeneau AA; Miller VP; Crespi CL
    Drug Metab Dispos; 2000 Dec; 28(12):1440-8. PubMed ID: 11095581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The combination of chemical and antibody inhibitors for superior P450 3A inhibition in reaction phenotyping studies.
    Rock DA; Foti RS; Pearson JT
    Drug Metab Dispos; 2008 Dec; 36(12):2410-3. PubMed ID: 18765682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ethanol inhibits in-vitro metabolism of nifedipine, triazolam and testosterone in human liver microsomes.
    Patki KC; Greenblatt DJ; von Moltke LL
    J Pharm Pharmacol; 2004 Aug; 56(8):963-6. PubMed ID: 15285839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanism of cytochrome P450-3A inhibition by ketoconazole.
    Greenblatt DJ; Zhao Y; Venkatakrishnan K; Duan SX; Harmatz JS; Parent SJ; Court MH; von Moltke LL
    J Pharm Pharmacol; 2011 Feb; 63(2):214-21. PubMed ID: 21235585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine.
    Galetin A; Clarke SE; Houston JB
    Drug Metab Dispos; 2003 Sep; 31(9):1108-16. PubMed ID: 12920166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development.
    Mori K; Hashimoto H; Takatsu H; Tsuda-Tsukimoto M; Kume T
    Xenobiotica; 2009 Jun; 39(6):415-22. PubMed ID: 19480547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amenamevir: Studies of Potential CYP3A-Mediated Pharmacokinetic Interactions With Midazolam, Cyclosporine, and Ritonavir in Healthy Volunteers.
    Adeloye T; Sahgal O; Puri A; Warrington S; Endo T; Dennison J; Johnston A
    Clin Pharmacol Drug Dev; 2018 Nov; 7(8):844-859. PubMed ID: 30044899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.